Global Gastrointestinal Stromal Tumor (GIST) Market Spotlight: 2018-2028 - ResearchAndMarkets.com

May 14, 2018

DUBLIN--(BUSINESS WIRE)--May 14, 2018--The “Market Spotlight: Gastrointestinal Stromal Tumor (GIST)” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the gastrointestinal stromal tumor (GIST) market, comprising key marketed and pipeline drugs, clinical trials, key upcoming events, key regulatory events, patent information, a 10-year disease incidence forecast, and drug-specific revenue forecasts.

Key Takeaways

The author estimates that in 2016, there were 96,400 incident cases of gastrointestinal stromal tumor (GIST) worldwide, and expects that number to increase to 105,600 incident cases by 2025. Incidence (per 100,000) is highest in Asia and lowest in Northern America. The approved drugs in the GIST space target platelet-derived growth factor receptor (PDGFR), BCR-ABL fusion protein, vascular endothelial growth factor (VEGF) receptor, KIT/c-KIT, Raf kinase, and FMS-like tyrosine kinase 3. All of the marketed drugs for GIST are administered via the oral route. The majority of industry-sponsored drugs in active clinical development for GIST are in Phase II, with only three drugs in Phase III. Therapies in mid- to late-stage development for GIST focus on a variety of targets. The majority of pipeline drugs in mid- to latestage development for GIST are administered via the oral route. Sutent’s (sunitinib) US method of use patent is set to expire in December 2020, which will open the door to generic entry. Gleevec (imatinib) sales ranked highest in the GIST space during 2012-16. The distribution of clinical trials across Phases I-IV indicates that the majority of trials for GIST have been in early and midphases of development, with 82.7% of trials in Phase I-II and only 17.3% in Phase III-IV. The US has a substantial lead in the number of GIST clinical trials globally. The UK and France lead the major EU markets, while Japan has the top spot in Asia. Clinical trial activity in the GIST space is dominated by completed trials. Novartis has the highest number of completed clinical trials for GIST, followed by Pfizer. Novartis leads industry sponsors with the highest number of clinical trials for GIST.

Key Topics Covered:

Overview Key Takeaways Disease Background Treatment Epidemiology Marketed Drugs Pipeline Drugs Key Upcoming Events Key Regulatory Events Parent Patents Revenue Opportunity Clinical Trial Landscape Bibliography Appendix

For more information about this report visit https://www.researchandmarkets.com/research/przlw2/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514005853/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 10:34 AM/DISC: 05/14/2018 10:34 AM


Update hourly